^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tecentriq (atezolizumab)

    i
    Other names: MPDL3280A, RG7446, RO5541267, MPDL-3280A, RG-7446, RO 5541267, RO 554-1267, RG7446-42, RO-5541267, MPDL 3280A, RG 7446, RG744642, RG 744642, RG-744642, RO-5541267 IV, MPDL 3280A IV
    Company:
    Roche
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    1d
    IMMUNOCELL: Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P=N/A, N=4, Terminated, Assistance Publique - Hôpitaux de Paris | N=120 --> 4 | Trial completion date: Sep 2027 --> Sep 2025 | Recruiting --> Terminated; Abandon of study
    Enrollment change • Trial completion date • Trial termination • IO biomarker
    |
    Tecentriq (atezolizumab)
    1d
    A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101) (clinicaltrials.gov)
    P1, N=590, Recruiting, GlaxoSmithKline | N=316 --> 590
    Enrollment change • Pan tumor
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Erbitux (cetuximab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • Imfinzi (durvalumab) • risvutatug rezetecan (GSK5764227)
    1d
    MTX-GPC3-303: A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC (clinicaltrials.gov)
    P1, N=70, Recruiting, Myeloid Therapeutics | N=48 --> 70 | Trial completion date: May 2026 --> May 2028 | Trial primary completion date: Jul 2025 --> Dec 2027
    Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    1d
    Efficacy and safety of Atezolizumab plus Bevacizumab and Lenvatinib as first-line systemic therapies for hepatocellular carcinoma: A real-world study. (PubMed, PLoS One)
    In conclusion, the study demonstrates that ATEZO/BEV significantly improves OS compared to LEN in patients with unresectable HCC, despite similar PFS, ORR, and DCR. Both treatments have comparable safety profiles.
    Retrospective data • Journal • Real-world evidence
    |
    AFP (Alpha-fetoprotein)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Lenvima (lenvatinib)
    2d
    SKYSCRAPER-06: A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=542, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Trial completion • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • pemetrexed • tiragolumab (RG6058)
    2d
    Clinical Feasibility of Circulating Tumor DNA in Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab. (PubMed, Liver Cancer)
    Additionally, ctDNA maxVAF demonstrated independent prognostic value in patients treated with first-line atezo/bev. Liquid biopsy using ctDNA can help address challenges associated with limited tissue-based genomic profiling in advanced HCC.
    Journal • PD(L)-1 Biomarker • IO biomarker • Circulating tumor DNA
    |
    Guardant360® CDx
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    3d
    ABATE-MASLD: The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD (clinicaltrials.gov)
    P2/3, N=20, Recruiting, Eastern Hepatobiliary Surgery Hospital
    New P2/3 trial
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    3d
    DAREON-8: DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=46, Active, not recruiting, Boehringer Ingelheim | Trial primary completion date: Dec 2025 --> Sep 2026
    Trial primary completion date
    |
    cisplatin • Tecentriq (atezolizumab) • carboplatin • Imfinzi (durvalumab) • etoposide IV • obrixtamig (BI 764532)
    3d
    Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer (clinicaltrials.gov)
    P2, N=37, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive
    |
    Tecentriq (atezolizumab) • Cotellic (cobimetinib) • Halaven (eribulin mesylate)
    3d
    IMMUNOGLYPIC: Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy (clinicaltrials.gov)
    P=N/A, N=240, Recruiting, Assistance Publique - Hôpitaux de Paris | N=120 --> 240
    Enrollment change • IO biomarker
    |
    Tecentriq (atezolizumab) • Imfinzi (durvalumab)
    4d
    Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma (clinicaltrials.gov)
    P=N/A, N=30, Not yet recruiting, Third Affiliated Hospital, Sun Yat-Sen University
    New trial
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • epirubicin
    4d
    MORPHEUS-EC: A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) (clinicaltrials.gov)
    P1/2, N=214, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed | N=410 --> 214
    Trial completion • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    HER-2 negative • HER-2 expression
    |
    cisplatin • Tecentriq (atezolizumab) • paclitaxel • 5-fluorouracil • Cotellic (cobimetinib) • Cyramza (ramucirumab) • oxaliplatin • leucovorin calcium • tiragolumab (RG6058) • pegvorhyaluronidase alfa (PEGPH20) • Aphexda (motixafortide)